Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8263362 | 0.93 | SLC2A1 (0.40) | SLC2A1JAK2JAK1USP30GPR119 | |
| SCHEMBL13490836 | 0.93 | SLC2A1 (0.40) | SLC2A1JAK2JAK1USP30GPR119 | |
| SCHEMBL8262771 | 0.93 | GPR119 (0.39) | SLC2A1JAK2JAK1USP30GPR119 | |
| SCHEMBL8265157 | 0.93 | SLC2A1 (0.43) | SLC2A1JAK2JAK1USP30GPR119 | |
| SCHEMBL13490821 | 0.90 | JAK2 (0.49) | JAK2JAK1USP30GPR119UBE2M | |
| SCHEMBL13490824 | 0.89 | JAK2 (0.42) | JAK2JAK1USP30GPR119MGAT2 | |
| SCHEMBL8264159 | 0.89 | GPR119 (0.42) | SLC2A1JAK2JAK1USP30GPR119 | |
| SCHEMBL8263872 | 0.88 | JAK2 (0.43) | JAK2JAK1USP30GPR119 | |
| SCHEMBL8264180 | 0.87 | JAK2 (0.43) | JAK2JAK1USP30GPR119UBE2M | |
| SCHEMBL8263838 | 0.87 | GPR119 (0.41) | JAK2JAK1USP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | SLC2A1 1474/4885JAK2 415/4885JAK1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.